The European Medicines Agency has officially authorized Awiqli, a novel long-acting insulin, for treating adults with diabetes across the European Union. This approval introduces a convenient once-weekly injection schedule, promising to enhance adherence and improve the quality of life for individuals managing both type 1 and type 2 diabetes.
Awiqli’s Efficacy in Managing Type 1 and Type 2 Diabetes
Awiqli has demonstrated significant effectiveness in controlling blood glucose levels in clinical trials involving over 3,500 adults with type 2 diabetes and 582 adults with type 1 diabetes. For type 2 diabetes patients, Awiqli alone or combined with other medications achieved similar reductions in HbA1c levels compared to daily insulins like degludec or glargine. In type 1 diabetes, when paired with short-acting insulin, Awiqli provided comparable glycemic control over a 52-week period.
Safety Measures and Side Effects of Awiqli
While Awiqli offers the benefit of reduced injection frequency, it is associated with an increased risk of hypoglycemia, particularly in type 1 diabetes patients. Common side effects include low blood glucose levels, necessitating regular blood sugar monitoring and dose adjustments. The marketing authorization holder has committed to providing comprehensive educational materials to prevent medication errors and ensure safe usage during the transition from daily insulins.
• A once-weekly regimen may improve patient compliance and reduce daily injection fatigue
• Awiqli’s comparable effectiveness to daily insulins offers a flexible treatment alternative
• Increased hypoglycemia risk in type 1 diabetes requires careful monitoring and patient education
• Financial and accessibility considerations may influence adoption rates across the EU
Healthcare providers are encouraged to evaluate the benefits of Awiqli for each patient, considering factors such as lifestyle, adherence potential, and risk of hypoglycemia. Patients should engage in thorough discussions with their healthcare teams to understand dosing adjustments and integrate Awiqli into their diabetes management plans effectively. Continuous monitoring and support will be crucial to maximize the therapeutic advantages of this new treatment option.
This article has been prepared with the assistance of AI and reviewed by an editor. For more details, please refer to our Terms and Conditions. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author.
